Navigation Links
Helix BioPharma to Present at the BioFinance 2009 Conference
Date:4/24/2009

AURORA, Ontario, April 24 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced that John Docherty, president and chief operating officer, will present at the BioFinance 2009 Investor Conference at 3:00 p.m. EDT on Wednesday, April 29, at The Toronto Marriott in Toronto. Mr. Docherty will provide an overview of the company's leading technology platforms, DOS47 and Biphasix(TM), and its current product development programs, L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on April 29, 2009.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".

    For further information contact:

    Investor & Media Relations
    Ian Stone                           Robert Flamm, Ph.D.
    Russo Partners LLC                  Russo Partners LLC
    Tel: (619) 814-3510                 Tel: (212) 845-4226
    Fax: (619) 955-5318                 Email:
    Email:                               robert.flamm@russopartnersllc.com
     ian.stone@russopartnersllc.com     www.russopartnersllc.com

This News Release contains certain forward-looking statements regarding the Company's planned presentation at the BioFinance 2009 Investor Conference and the Company's research and development initiatives, which statements can be identified
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 New test innovations will be the ... (IVD) test industry, especially as companies struggle with reimbursement ... more than 25 testing innovations in important disease areas ... IVD products. Kalorama details the new approaches its biennial survey ... In Vitro Diagnostic Tests , 9th Edition . ...
(Date:10/22/2014)... The North American crystal oscillator market report ... analysis and forecast of revenue. This market was valued ... reach $623.6 million by 2018, at a CAGR of ... TOC of the North American crystal oscillator market report, ... This also provides a glimpse of the segmentation of ...
(Date:10/22/2014)... 2014 Currently offering a comprehensive ... D Weighing, Rice Lake, and Ohaus, Pipette.com has ... The Sartorius CPA Semi-Micro Balance is ideal for ... and user-friendly laboratory balance. , Sartorius is a ... laboratory balances are well known for their high ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
Breaking Biology Technology:Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... 11 Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ... Blair & Company 28th Annual Growth Stock Conference in ... Time., A live webcast of the presentation can ... . The webcast will,be archived for replay following ...
... Rosetta Genomics has Signed a Binding Term Sheet to Acquire Parkway ... ... Significantly Streamline the Development and Commercialization of Rosetta Genomics, microRNA-based ... Needs to Market and Sell its microRNA-based Tests in the U.S. and ...
... DANBURY, Conn., June 11 Biodel Inc. (Nasdaq:,BIOD) today ... as,a new member of its Board of Directors, effective ... of Diabetes Technology,Consultants where he advises Fortune 500 companies ... welcome Barry to our Board of Directors at such ...
Cached Biology Technology:Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 2Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 3Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 4Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 5Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 6Barry Ginsberg, M.D., Ph.D. Elected to Biodel's Board of Directors 2
(Date:10/25/2014)... 2014 A recent report, "Genetic Testing Market ... and future genetic testing market. A comprehensive introduction of ... in this report. On account of our analysis of ... strengths and challenges; forecast for genetic testing has been ... grow at a CAGR of around 9% during 2013-2018. ...
(Date:10/22/2014)... Medicine® scientists helps explain how bipolar disorder affects the ... therapies to treat the mental illness. , Scientists ... method recognized with the 2014 Nobel Prize in ... from mice with bipolar-like behaviors. In the synapses (where ... structures with concentrated levels of ANK3 -- the gene ...
(Date:10/22/2014)... 20, 2014  Leading identity analyst firm Acuity Market ... the world,s population will have a chip-based National eID ... . Asia , with its ... for more than 60% of all National eID cards ... -- "The Global National eID Industry Report: ...
Breaking Biology News(10 mins):Genetic Testing Market Outlook 2018 2Bipolar disorder discovery at the nano level 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2
... Calif., Nov. 19, 2012 Medbox, Inc. (Ticker: MDBX) ... press release they have received many inquiries from shareholders ... during last week,s volatile trading. These inquiries were responded ... to shareholder rapport. In other news, ...
... media only" box at the end of the release ... mouse model of multiple sclerosis (MS), researchers funded by ... to selectively inhibit the part of the immune system ... fibers and facilitates electrical communication between brain cells. ...
... 16 Penguins that face the bitter cold and icy ... warmth during storms. Mathematicians at the University of California, Merced ... aims solely to minimize its own heat loss. Surprisingly, the ... sharing of heat. The results are published in the online ...
Cached Biology News:Medbox Communicates with Shareholders, Comments on Pending Transition to OTC Bulletin Board, and Announces Appearance on Fox Business News Channel 2Research breakthrough selectively represses the immune system 2Research breakthrough selectively represses the immune system 3Research breakthrough selectively represses the immune system 4New model reveals how huddling penguins share heat fairly 2New model reveals how huddling penguins share heat fairly 3
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... application for DNA and protein sequence ... makes complex computational analyses of sequence ... very latest computing technology to set ... are analysed. Features include: Sequence Annotation, ...
... Cytokeratin TYPE II Reacts with most ... epidermal cell keratin of 86 and 58kD ... Broad keratin reactivity is found on human ... Immunogen: Human epidermal cells ...
... The CHEMICON XpressPack™ Colorimetric Detection System ... detection of amplified DNA generated by an ... of a selected target of interest. ... Colorimetric Detection System is a hybridization capture ...
Biology Products: